title: The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.
abstract: This article discusses current practice in the treatment of conjunctivitis and how the use of topical moxifloxacin can increase therapeutic effectiveness, reduce treatment failures and, consequently, be cost effective and reduce the societal burden of the disorder. Current practice and effectiveness data were derived from the literature. Data on healthcare utilization as a result of treatment failure were collected by survey and the cost of treatment was defined using national costings. A decision-analytic model to assess cost effectiveness was developed and the impact on the healthcare budget was calculated to define the health economic impact. Bacterial conjunctivitis represents a significant health problem and accounts for an estimated 1-1.5% of primary-care consultations. The disorder is highly contagious and causes a substantial healthcare and societal burden. Bacterial conjunctivitis is generally self-limiting, resolving within 1-2 weeks. However, the use of antibacterials significantly improves clinical and microbiological remission, shortens symptom duration, and enables more effective use of healthcare resources, compared with placebo. From a health economic perspective this benefits the healthcare system and society, since fewer healthcare resources are needed and the adult affected, or the parent/caregiver of the child affected, can return to full work capacity sooner, reducing loss of productivity. Treatment strategies vary significantly between countries. Most patients are first seen in primary care, where 'wait-and-see', lubrification and antiseptic or antibacterial treatment is provided. In Europe, when antibacterials are prescribed most general practitioners (GPs) prescribe a broad-spectrum topical antibacterial. The most commonly used drugs are chloramphenicol and fusidic acid, with fluoroquinolones rarely reported as first-line treatment by GPs. At the specialist (ophthalmologist) level, or for second-line treatment at the GP level, topical antibacterials are frequently used. However, in most countries, topical fluoroquinolones, particularly those recently approved by the European Medicines Agency, such as topical levofloxacin and topical moxifloxacin, are rarely used and instead are reserved for use as a last resort. In other parts of the world topical lomefloxacin, gatifloxacin and/or besifloxacin are also available. The strategy of using novel topical fluoroquinolones as a last resort reflects a belief that the use of topical fluoroquinolones may enhance the development of resistance, jeopardizing future availability of antibacterial treatment for ocular infections. In fact, most cases of bacterial resistance arise as a result of systemic treatment. Thus, this concern should not be extrapolated to topical use of fluoroquinolones, which results in antibacterial concentrations at the ocular surface that can significantly exceed mutant prevention concentrations. In addition, with products such as topical moxifloxacin, a dual-step mutation is required for resistance to emerge. Moxifloxacin restricts the selection of resistant mutants, meaning that emergence of resistance is unlikely. The strategy of not using the most effective fluoroquinolones such as topical moxifloxacin may lead to more patients with no improvement or worsening of symptoms, requiring re-intervention, additional examination and new treatment; these outcomes are defined as 'treatment failures'. Treatment failures cause an extra societal burden and increased costs due to the extra healthcare resources required (additional GP/specialist visits, laboratory tests, additional treatment, etc.). Compared with non-fluoroquinolones, topical moxifloxacin has a higher potency and faster in vitro 'speed-to-kill'. It has also been shown that, within the fluoroquinolone class, topical moxifloxacin and besifloxacin achieve the highest mean concentrations in conjunctival tissue, have the longest residence times and display favourable area under the concentration-time curve from time zero to 24 hours (AUC(24))/minimum inhibitory concentration ratio required to inhibit the growth of 90% of organisms (MIC(90)) and thus favourable pharmacokinetic/pharmacodynamic characteristics. This can result in reduced time-to-cure and a lower number of treatment failures, leading to better disease management and a healthcare-economic benefit arising from the associated reduction in utilization of healthcare resources. The high potency and mean concentration in conjunctival tissue combined with the long residence time of topical moxifloxacin enables a dosing strategy of three times daily for 5 days. Topical moxifloxacin is also the first ophthalmic antibacterial in Europe provided as a multidose, self-preserved, topical solution, thus avoiding the risk of benzalkonium chloride preservative-related allergic reactions and swelling. In addition, topical moxifloxacin has a near neutral pH (6.8) and is well tolerated by patients. Given the characteristics of the novel topical fluoroquinolones, a change in the healthcare treatment strategy for acute infectious conjunctivitis is to be recommended. Topical application of fluoroquinolones, such as moxifloxacin multidose self-preserved solution, should be considered earlier in the treatment path for conjunctivitis. Notwithstanding the premium price attached to this novel topical antibacterial, use of topical moxifloxacin for bacterial conjunctivitis can be cost effective and even generate total healthcare budget savings by reducing both the costs of managing treatment failures and the use of clinicians' time to manage such failures.
authors: Ocular Surface and Inflammation Department, Ophthalmology, Hospital Clinico de San Carlos, Madrid, Spain.|Universidad Complutense, Madrid, Spain.
authors: Jose
authors: J
authors: Benitez-Del-Castillo
authors: Alcon Research Ltd, Puurs, Belgium.
authors: Yves
authors: Y
authors: Verboven
authors: Alcon Research Ltd, Fort Worth, TX, USA.
authors: David
authors: D
authors: Stroman
authors: Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon and University of Lyon, Lyon, France. kodjikian.laurent@wanadoo.fr.|Laboratory of Biomaterials, Medical Devices and Matrix Remodelling, Claude Bernard Lyon I University, Lyon, France. kodjikian.laurent@wanadoo.fr.
authors: Laurent
authors: L
authors: Kodjikian
references: Curr Med Res Opin. 2007 Sep;23(9):2241-9
references: 17688706
references: Cornea. 2002 Oct;21(7 Suppl):S86-9
references: 12484705
references: BMJ. 2003 Oct 4;327(7418):789
references: 14525879
references: Clin Ophthalmol. 2009;3:553-7
references: 19898627
references: Expert Opin Pharmacother. 2009 Oct;10(15):2545-54
references: 19743941
references: Surv Ophthalmol. 2005 Nov;50 Suppl 1:S16-31
references: 16257308
references: Am J Ophthalmol. 2007 Aug;144(2):315-8
references: 17659971
references: J Pediatr Ophthalmol Strabismus. 2008 Nov-Dec;45(6):340-9
references: 19043945
references: Antimicrob Agents Chemother. 2001 Feb;45(2):433-8
references: 11158737
references: Br J Ophthalmol. 2003 Jul;87(7):834-8
references: 12812878
references: Am J Ophthalmol. 1991 Oct;112(4 Suppl):2S-9S
references: 1928269
references: Clin Ophthalmol. 2010 Apr 26;4:331-41
references: 20463802
references: Am J Ophthalmol. 1982 Mar;93(3):356-60
references: 7072798
references: Br Med J (Clin Res Ed). 1986 Dec 6;293(6560):1477-80
references: 3099921
references: Clin Microbiol Infect. 2002;8 Suppl 3:9-20; discussion 33-5
references: 12519345
references: Ophthalmology. 2006 Jun;113(6):955-9
references: 16603244
references: Lens Eye Toxic Res. 1992;9(3-4):361-75
references: 1301792
references: Ophthalmology. 2010 Dec;117(12):2372-8
references: 20656351
references: Lancet. 2005 Jul 2-8;366(9479):37-43
references: 15993231
references: MMWR Morb Mortal Wkly Rep. 2002 Mar 15;51(10):205-7
references: 11922188
references: Clin Ther. 2010 Mar;32(3):454-71
references: 20399984
references: Acta Ophthalmol. 2008 Feb;86(1):5-17
references: 17970823
references: Practitioner. 1998 Apr;242(1585):305
references: 10492990
references: Br J Gen Pract. 1993 Nov;43(376):459-62
references: 8292417
references: Br J Gen Pract. 2001 Jun;51(467):473-7
references: 11407054
references: Ophthalmology. 2008 Jan;115(1):51-6
references: 17572497
references: Surv Ophthalmol. 2005 Nov;50 Suppl 1:S1-6
references: 16257307
references: Ann Pharmacother. 2005 Oct;39(10):1737-40
references: 16105873
references: J Ocul Pharmacol Ther. 2010 Oct;26(5):449-58
references: 20874668
references: Antimicrob Agents Chemother. 1988 Dec;32(12):1820-4
references: 3072923
references: J Cataract Refract Surg. 2010 Sep;36(9):1499-502
references: 20692561
references: Ophthalmology. 2005 Nov;112(11):1987
references: 16183128
references: Ophthalmology. 1999 Jul;106(7):1313-8
references: 10406613
references: Fam Pract. 2002 Dec;19(6):658-60
references: 12429670
references: BMC Fam Pract. 2007 Sep 16;8:54
references: 17868475
references: Drugs. 1996 Oct;52(4):526-40
references: 8891465
references: Expert Opin Pharmacother. 2007 Aug;8(12):1903-21
references: 17696792
references: Eye (Lond). 2007 Jul;21(7):990-4
references: 16732216
references: Clin Evid. 2002 Jun;(7):574-9
references: 12230683
references: J Antimicrob Chemother. 2010 Jul;65(7):1441-7
references: 20435780
references: Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3425-9
references: 17652708
references: Cornea. 2008 Apr;27(3):314-9
references: 18362660
references: J Ocul Pharmacol Ther. 2010 Dec;26(6):591-5
references: 20925517
references: J Infect Dis. 1991 Dec;164(6):1113-8
references: 1955711
references: J Pediatr Ophthalmol Strabismus. 2006 Jan-Feb;43(1):19-26
references: 16491721
references: Adv Ther. 2008 Oct;25(10):979-94
references: 18836691
references: Arch Ophthalmol. 1984 May;102(5):711-3
references: 6721759
references: Indian J Ophthalmol. 2010 Nov-Dec;58(6):497-507
references: 20952834
references: Clin Ophthalmol. 2010 Feb 02;4:41-5
references: 20169048
references: Surv Ophthalmol. 2004 Mar;49 Suppl 2:S79-83
references: 15028483
references: Arch Ophthalmol. 2005 Jan;123(1):39-44
references: 15642810
references: Surv Ophthalmol. 2005 Nov;50 Suppl 1:S7-15
references: 16257313
references: Ophthalmologe. 2007 Jan;104(1):21-7
references: 17160378
references: BMJ. 2006 Aug 12;333(7563):321
references: 16847013
references: Infez Med. 2007 Dec;15(4):211-36
references: 18162733
references: J Cataract Refract Surg. 2010 Sep;36(9):1588-98
references: 20692574
references: Pediatr Infect Dis J. 1989 May;8(5):287-90
references: 2631693
references: Clin Drug Investig. 2010;30(10):675-85
references: 20629472
references: Ophthalmology. 2005 Nov;112(11):1992-6
references: 16183125
references: Infect Control Hosp Epidemiol. 1995 Apr;16(4):210-6
references: 7636168
references: Br J Gen Pract. 2005 Dec;55(521):924-30
references: 16378561
references: BMJ. 1997 Sep 27;315(7111):816-7
references: 9345194
references: Semin Respir Crit Care Med. 2005 Dec;26(6):563-74
references: 16388428
references: West J Med. 2000 Sep;173(3):202-5
references: 10986192
references: Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001211
references: 16625540
references: Clin Ophthalmol. 2008 Mar;2(1):241-2
references: 19668414
references: N Engl J Med. 1983 Jun 23;308(25):1536
references: 6855828
references: Acad Emerg Med. 2007 Jan;14(1):1-5
references: 17119185
references: Arch Ophthalmol. 2005 Sep;123(9):1282-3
references: 16157821
references: Cornea. 2000 Sep;19(5):659-72
references: 11009318
references: Am J Gastroenterol. 2000 Jun;95(6):1606
references: 10894622
references: J Fr Ophtalmol. 2010 Apr;33(4):227-33
references: 20223557
references: Adv Ther. 2007 Sep-Oct;24(5):1098-111
references: 18029337
references: Anim Biotechnol. 2002 May;13(1):71-84
references: 12212946
references: Adv Ther. 2010 Jan;27(1):39-47
references: 20174904
references: Ophthalmology. 2009 Sep;116(9):1615-1623.e1
references: 19643483
references: Curr Eye Res. 2008 Nov;33(11):907-11
references: 19085372
references: Surv Ophthalmol. 2005 Nov;50 Suppl 1:S55-63
references: 16257311
references: Int J Antimicrob Agents. 2008 Feb;31 Suppl 1:S35-9
references: 18164598
references: Cornea. 2007 Feb;26(2):194-8
references: 17251812
references: Br J Ophthalmol. 1988 Oct;72(10):733-6
references: 3191073